GENC

Gencor is a rare debt-free small-cap: $0 long-term debt, liabilities/equity of just 0.05x, $26.6M cash, and $207M of current assets against only $8.81M of current liabilities. Net income has recovered impressively from a -$372K loss in FY2022 to $15.7M in FY2025 (+7.6% YoY), and diluted EPS of $1.07 (+8.1%) puts the stock at a modest 14x P/E and 1.9x sales. Because current assets ($207M) dwarf the operating footprint, a large slice of the $220M market cap is effectively backed by cash and an investment portfolio — the MD&A explicitly flags 'income from investees' and 'the performance of the investment portfolio' as material — so the operating business itself trades very cheaply. That asset backing is the core of the hold: it limits downside.

The problem is that this value sits idle. ROE is only 7.4% precisely because equity ($212M) is bloated with under-deployed capital, and management states it has 'no intention to pay cash dividends' and made no buybacks in the quarter. Growth is anemic: revenue rose just 2.0% to $115M, gross margin slipped to 27.5% from 27.7%, and the exit rate is deteriorating — Q4 revenue fell 10.0% and Q4 gross margin dropped to 24.2% from 25.6%. Most concerning, operating cash flow collapsed 67% to $3.07M while capex more than doubled, so reported earnings are not converting to cash, likely tied up in seasonal working capital.